



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Cedazuridine

Item No. 38767

**CAS Registry No.:** 1141397-80-9  
**Formal Name:** (4R)-2'-deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-uridine  
**Synonym:** E7727  
**MF:** C<sub>9</sub>H<sub>14</sub>F<sub>2</sub>N<sub>2</sub>O<sub>5</sub>  
**FW:** 268.2  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Cedazuridine is supplied as a crystalline solid. A stock solution may be made by dissolving the cedazuridine in the solvent of choice, which should be purged with an inert gas. Cedazuridine is soluble in DMSO.

### Description

Cedazuridine is an inhibitor of cytidine deaminase (IC<sub>50</sub> = 0.4 μM).<sup>1</sup> It increases plasma levels of decitabine *via* inhibition of its metabolism by cytidine deaminase in rhesus monkeys when administered at doses of 1 and 10 mg/kg. Cedazuridine (3 mg/kg) induces decreases in leukemic cell expansion in combination with orally administered 5-azacytidine (Item No. 11164), which is inactive as a single agent, in the bone marrow and spleen in a MOLM-13 acute myeloid leukemia (AML) mouse xenograft model.<sup>2</sup> Formulations containing cedazuridine in combination with decitabine have been used in the treatment of myelodysplastic syndrome (MDS).

### References

1. Ferraris, D., Duvall, B., Delahanty, G., *et al.* Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. *J. Med. Chem.* **57**(6), 2582-2588 (2014).
2. Ramsey, H.E., Ogenesian, A., Gorska, A.E., *et al.* Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. *Target Oncol.* **15**(2), 231-240 (2020).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/11/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM